Fast tracking drugs to patients

Regulatory approval of drugs can be an obstacle course and is a process that frequently comes under fire for being too rapid or too lax. Critics often complain that pharmaceuticals are approved too slowly by a process that is too costly and byzantine, which has fatal effects for patients when life‐saving anti‐cancer and anti‐HIV drugs are involved. The US Food and Drug Administration (FDA), the agency responsible for approving new drugs, has...